A new test with ‘mini-guts’ or organoids can inform Cystic Fibrosis (CF) patients and their physicians whether they can benefit from a novel treatment against the disease. A major problem in the treatment of CF is the enormous genetic variability among patients. This means that for up to 50% of them it is unclear if or when they will be included in a clinical trial. Because for patients that respond to the treatment, the benefits may be lifesaving.
This story describes the first patient that has been treated because of organoid work at the UMCU, the Hubrecht Institute and the HUB.